by James Radke, PhD | Mar 15, 2023
Jonathan Barratt, PhD, FRCP, Professor of Renal Medicine, University of Leicester, UK, gives an overview of immunoglobulin A (IgA) nephropathy. As Dr. Barratt explains, IgA nephropathy is a rare kidney disease characterized by build-up of IgA deposits in the...
by James Radke, PhD | Mar 2, 2023
Allen Davidoff, PhD, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disorder characterized by the...
by James Radke, PhD | Feb 24, 2023
The U.S. Food and Drug Administration has approved efanesoctocog alfa for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia A. Angela Weyand,...
by James Radke, PhD | Feb 21, 2023
Allen Davidoff, PhD, CEO of XORTX Therapeutics, gives an overview of autosomal dominant polycystic kidney disease (ADPKD). As Dr. Davidoff explains, ADPKD is a genetic disorder characterized by the formation of cysts in the kidneys. The most common symptoms –...
by James Radke, PhD | Feb 17, 2023
The U.S. Food and Drug Administration has approved velmanase alfa-tycv for the treatment of non-central nervous system manifestations of alpha-mannosidosis adult and pediatric patients. Alpha mannosidosis is a multisystemic, lysosomal disorder caused by a deficiency...
